Gui-Qi Zhu

List of Publications by Citations

58 papers	898 citations	17 h-index	26 g-index
61 ext. papers	1,147 ext. citations	4.4 avg, IF	4 L-index

#	Paper	IF	Citations
58	Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy. *Alimentary Pharmacology and Therapeutics*, **2015**, 41, 624-35	6.1	57
57	Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma. *Oncotarget*, **2016**, 7, 21753-62	3.3	55
56	The miR-561-5p/CXCL1 Signaling Axis Regulates Pulmonary Metastasis in Hepatocellular Carcinoma Involving CXCR1 Natural Killer Cells Infiltration. *Theranostics*, **2019**, 9, 4779-4794	12.1	43
55	Preoperative platelet to lymphocyte ratio is a valuable prognostic biomarker in patients with colorectal cancer. *Oncotarget*, **2016**, 7, 25516-27	3.3	43
54	Association between sex-specific serum uric acid and non-alcoholic fatty liver disease in Chinese adults: a large population-based study. *Medicine (United States)*, **2015**, 94, e802	1.8	40
53	Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation. *Oncotarget*, **2016**, 7, 30642-58	3.3	40
52	Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma. *Scientific Reports*, **2016**, 6, 33743	4.9	38
51	Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis. *Oncotarget*, **2015**, 6, 18151-61	3.3	33
50	Metabolic syndrome contributes to an increased recurrence risk of non-metastatic colorectal cancer. *Oncotarget*, **2015**, 6, 19880-90	3.3	32
49	Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer. *Alimentary Pharmacology and Therapeutics*, **2014**, 40, 759-70	6.1	26
48	Increased levels of low-density lipoprotein cholesterol within the normal range as a risk factor for nonalcoholic fatty liver disease. *Oncotarget*, **2016**, 7, 5728-37	3.3	25
47	Prognostic alternative mRNA splicing signature in hepatocellular carcinoma: a study based on large-scale sequencing data. *Carcinogenesis*, **2019**, 40, 1077-1085	4.6	23
46	Increased levels of systolic blood pressure within the normal range are associated with significantly elevated risks of nonalcoholic fatty liver disease. *Medicine (United States)*, **2015**, 94, e842	1.8	22
45	Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1. *Medicine (United States)*, **2016**, 95, e3004	1.8	22
44	Identification and validation of tumour microenvironment-based immune molecular subgroups for gastric cancer: immunotherapeutic implications. *Cancer Immunology, Immunotherapy*, **2020**, 69, 1057-1069	7.4	20
43	A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis. *Oncotarget*, **2015**, 6, 26757-69	3.3	20
42	Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target. *Expert Opinion on Therapeutic Targets*, **2015**, 19, 675-85	6.4	19

#	Reference	IF	Citations
41	HNRNPAB-regulated lncRNA-ELF209 inhibits the malignancy of hepatocellular carcinoma. *International Journal of Cancer*, **2020**, 146, 169-180	7.5	17
40	Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease. *Expert Opinion on Therapeutic Targets*, **2016**, 20, 375-87	6.4	16
39	Decellularization technology in CNS tissue repair. *Expert Review of Neurotherapeutics*, **2015**, 15, 493-500	4.3	16
38	Network meta-analysis of randomized controlled trials: efficacy and safety of UDCA-based therapies in primary biliary cirrhosis. *Medicine (United States)*, **2015**, 94, e609	1.8	16
37	The role of lncRNAs in hepatocellular carcinoma: opportunities as novel targets for pharmacological intervention. *Expert Review of Gastroenterology and Hepatology*, **2016**, 10, 331-40	4.2	16
36	Platelet-to-Lymphocyte Ratio: A Novel Prognostic Factor for Prediction of 90-day Outcomes in Critically Ill Patients With Diabetic Ketoacidosis. *Medicine (United States)*, **2016**, 95, e2596	1.8	16
35	Nonalcoholic fatty liver disease: a negative risk factor for colorectal cancer prognosis. *Medicine (United States)*, **2015**, 94, e479	1.8	15
34	Stratified neutrophil-to-lymphocyte ratio accurately predict mortality risk in hepatocellular carcinoma patients following curative liver resection. *Oncotarget*, **2016**, 7, 5429-39	3.3	15
33	Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis. *Expert Review of Anti-Infective Therapy*, **2017**, 15, 503-513	5.5	14
32	Kidney bioengineering in regenerative medicine: An emerging therapy for kidney disease. *Cytotherapy*, **2016**, 18, 186-97	4.8	14
31	Conditional survival estimate of acute-on-chronic hepatitis B liver failure: a dynamic prediction based on a multicenter cohort. *Oncotarget*, **2015**, 6, 23261-71	3.3	12
30	Efficacy of prophylactic probiotics in combination with antibiotics versus antibiotics alone for colorectal surgery: A meta-analysis of randomized controlled trials. *Journal of Surgical Oncology*, **2018**, 117, 1394-1404	2.8	11
29	Comparative efficacy of oral nucleotide analogues for the prophylaxis of hepatitis B virus recurrence after liver transplantation: a network meta-analysis. *Expert Review of Anti-Infective Therapy*, **2016**, 14, 979-87	5.5	11
28	Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients. *Journal of Translational Medicine*, **2019**, 17, 203	8.5	10
27	Comparative efficacy and safety between ablative therapies or surgery for small hepatocellular carcinoma: a network meta-analysis. *Expert Review of Gastroenterology and Hepatology*, **2018**, 12, 935-945	4.2	10
26	Establishment and Validation of SSCLIP Scoring System to Estimate Survival in Hepatocellular Carcinoma Patients Who Received Curative Liver Resection. *PLoS ONE*, **2015**, 10, e0129000	3.7	10
25	Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis. *Oncotarget*, **2015**, 6, 24533-49	3.3	10
24	Systematic review with network meta-analysis: adjuvant chemotherapy for resected colorectal liver metastases. *Medicine (United States)*, **2015**, 94, e379	1.8	8

23	Autophagy in ethanol-exposed liver disease. *Expert Review of Gastroenterology and Hepatology*, **2015**, 9, 1031-7	4.2	8
22	Establishment and Validation of GV-SAPS II Scoring System for Non-Diabetic Critically Ill Patients. *PLoS ONE*, **2016**, 11, e0166085	3.7	8
21	Comparative efficacy and safety of immunosuppressive therapies for systemic sclerosis related interstitial lung disease: A Bayesian network analysis. *Modern Rheumatology*, **2020**, 30, 687-695	3.3	8
20	Aspartate aminotransferase-to-platelet ratio index predicts prognosis of hepatocellular carcinoma after postoperative adjuvant transarterial chemoembolization. *Cancer Management and Research*, **2019**, 11, 63-79	3.6	8
19	MACROD2 deficiency promotes hepatocellular carcinoma growth and metastasis by activating GSK-3β/β-catenin signaling. *Npj Genomic Medicine*, **2020**, 5, 15	6.2	7
18	Long-Term Survival Differences Between T1-2 Invasive Lobular Breast Cancer and Corresponding Ductal Carcinoma After Breast-Conserving Surgery: A Propensity-Scored Matched Longitudinal Cohort Study. *Clinical Breast Cancer*, **2019**, 19, e101-e115	3	7
17	Splicing factors: Insights into their regulatory network in alternative splicing in cancer. *Cancer Letters*, **2021**, 501, 83-104	9.9	7
16	Exosomal miR-3682-3p Suppresses Angiogenesis by Targeting ANGPT1 via the RAS-MEK1/2-ERK1/2 Pathway in Hepatocellular Carcinoma. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 633358	5.7	7
15	New advances in liver decellularization and recellularization: innovative and critical technologies. *Expert Review of Gastroenterology and Hepatology*, **2015**, 9, 1183-91	4.2	6
14	Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1. *Journal of Experimental and Clinical Cancer Research*, **2021**, 40, 171	12.8	6
13	Parabolic relationship between sex-specific serum high sensitive C reactive protein and non-alcoholic fatty liver disease in Chinese adults: a large population-based study. *Oncotarget*, **2016**, 7, 14241-50	3.3	5
12	Comparative Effectiveness of Radiofrequency Ablation, Surgical Resection and Transplantation for Early Hepatocellular Carcinoma by Cancer Risk Groups: Results of Propensity Score-Weighted Analysis. *OncoTargets and Therapy*, **2019**, 12, 10389-10400	4.4	4
11	Survival-Associated Alternative Messenger RNA Splicing Signatures in Pancreatic Ductal Adenocarcinoma: A Study Based on RNA-Sequencing Data. *DNA and Cell Biology*, **2019**, 38, 1207-1222	3.6	3
10	Recent advances in re-engineered liver: de-cellularization and re-cellularization techniques. *Cytotherapy*, **2015**, 17, 1015-24	4.8	3
9	Genetic Alterations and Transcriptional Expression of mA RNA Methylation Regulators Drive a Malignant Phenotype and Have Clinical Prognostic Impact in Hepatocellular Carcinoma. *Frontiers in Oncology*, **2020**, 10, 900	5.3	3
8	Identification and validation of a new gene signature predicting prognosis of hepatocellular carcinoma patients by network analysis of stemness indices. *Expert Review of Gastroenterology and Hepatology*, **2021**, 15, 699-709	4.2	3
7	Combined AFP-CRUT with microvascular invasion accurately predicts mortality risk in patients with hepatocellular carcinoma following curative liver resection. *Expert Review of Gastroenterology and Hepatology*, **2015**, 9, 1127-38	4.2	2
6	A multidimensional nomogram combining imaging features and clinical factors to predict the invasiveness and metastasis of combined hepatocellular cholangiocarcinoma. *Annals of Translational Medicine*, **2021**, 9, 1518	3.2	2

LIST OF PUBLICATIONS

5	Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study. *Molecular Oncology*, **2021**,	7.9	2
4	Profiles of alternative splicing landscape in breast cancer and their clinical significance: an integrative analysis based on large-sequencing data. *Annals of Translational Medicine*, **2021**, 9, 58	3.2	1
3	Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.. *BMC Cancer*, **2022**, 22, 316	4.8	1
2	Crosstalk Between Metabolism and Immune Activity Reveals Four Subtypes With Therapeutic Implications in Clear Cell Renal Cell Carcinoma.. *Frontiers in Immunology*, **2022**, 13, 861328	8.4	1
1	Risk stratification of LI-RADS M and LI-RADS 4/5 combined hepatocellular cholangiocarcinoma: prognostic values of MR imaging features and clinicopathological factors.. *European Radiology*, **2022**, 1	8	0